Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2019

Open Access 01-12-2019 | Carotid Stenosis | Research

Hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome

Authors: Giuseppina Piazzolla, Mafalda Candigliota, Margherita Fanelli, Anna Castrovilli, Elsa Berardi, Gianfranco Antonica, Stefano Battaglia, Vincenzo Solfrizzi, Carlo Sabbà, Cosimo Tortorella

Published in: Diabetology & Metabolic Syndrome | Issue 1/2019

Login to get access

Abstract

Background

Metabolic syndrome (MetS) is a clinical condition potentially promoting the development of atherosclerotic disease. To date, the clinical impact of elevated serum homocysteine (Hcy) levels in MetS is still under discussion. The aim of this cross sectional study was to evaluate the relationship between MetS and hyperhomocysteinemia and the potential role of Hcy in the pathogenesis of atherosclerotic complications of MetS.

Methods

We recruited 300 outpatients with MetS. All patients underwent a medical history collection, physical examination, blood sampling and carotid ultrasound echo-color Doppler. According to Hcy levels, MetS patients were divided into two groups: “normal” (< 10.7 μmol/l; n = 140, group 1) and “high” Hcy (≥ 10.7 μmol/l; n = 160, group 2). Comparisons between groups were made by Student’s t-test or Chi-square test. The effects of potential covariates on group differences were evaluated by general linear models. The relationships between continuous variables were assessed by simple or multiple correlation and by linear regression. Multiple regression models were built to evaluate the effects of Hcy, together with other potential risk factors, on carotid atherosclerosis.

Results

Patients with high Hcy were predominantly male and slightly older than group 1 patients. Smokers and non-smokers exhibited similar Hcy levels, nor was a statistical relationship between pack-years and Hcy observed. Group 2 showed lower levels of folic acid, vitamin D, high density lipoprotein (HDL)-cholesterol and glomerular filtration rate (e-GFR) than group 1, but higher levels of C-peptide, uric acid and triglycerides. In all patients, Hcy was positively correlated with C-peptide and uric acid and negatively with folic acid and e-GFR. Intima-media thickness (IMT) and carotid stenosis degree were significantly higher in patients with high Hcy and a positive relationship between Hcy and both IMT and carotid stenosis was detected in all patients. Finally, Hcy atherogenic effects were independent of other well-known atherosclerosis risk factors.

Conclusions

Our results highlight a link between MetS and hyperhomocysteinemia and a direct effect of Hcy on atherogenic process during MetS. Early correction of folic acid levels may contribute to prevent cardiovascular complications in MetS patients.
Literature
2.
go back to reference Catena C, Colussi G, Nait F, Capobianco F, Sechi LA. Elevated homocysteine levels are associated with the metabolic syndrome and cardiovascular events in hypertensive patients. Am J Hypertens. 2015;28:943–50.PubMedCrossRef Catena C, Colussi G, Nait F, Capobianco F, Sechi LA. Elevated homocysteine levels are associated with the metabolic syndrome and cardiovascular events in hypertensive patients. Am J Hypertens. 2015;28:943–50.PubMedCrossRef
3.
go back to reference Oron-Herman M, Rosenthal T, Sela BA. Hyperhomocysteinemia as a component of syndrome X. Metabolism. 2003;52:1491–5.PubMedCrossRef Oron-Herman M, Rosenthal T, Sela BA. Hyperhomocysteinemia as a component of syndrome X. Metabolism. 2003;52:1491–5.PubMedCrossRef
5.
go back to reference Kastorini CM, Panagiotakos DB, Georgousopoulou EN, Laskaris A, Skourlis N, Zana A, ATTICA Study Group, et al. Metabolic syndrome and 10-year cardiovascular disease incidence: the ATTICA study. Nutr Metab Cardiovasc Dis. 2016;26:223–31.PubMedCrossRef Kastorini CM, Panagiotakos DB, Georgousopoulou EN, Laskaris A, Skourlis N, Zana A, ATTICA Study Group, et al. Metabolic syndrome and 10-year cardiovascular disease incidence: the ATTICA study. Nutr Metab Cardiovasc Dis. 2016;26:223–31.PubMedCrossRef
7.
go back to reference Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.PubMedCrossRef Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.PubMedCrossRef
8.
go back to reference Škovierová H, Vidomanová E, Mahmood S, Sopková J, Drgová A, Červeňová T, et al. The molecular and cellular effect of homocysteine metabolism imbalance on human health. Int J Mol Sci. 2016;17:1733.PubMedCentralCrossRef Škovierová H, Vidomanová E, Mahmood S, Sopková J, Drgová A, Červeňová T, et al. The molecular and cellular effect of homocysteine metabolism imbalance on human health. Int J Mol Sci. 2016;17:1733.PubMedCentralCrossRef
9.
go back to reference Hannibal L, Blom HJ. Homocysteine and disease: causal associations or epiphenomenons? Mol Aspects Med. 2017;53:36–42.PubMedCrossRef Hannibal L, Blom HJ. Homocysteine and disease: causal associations or epiphenomenons? Mol Aspects Med. 2017;53:36–42.PubMedCrossRef
10.
go back to reference Vaughn JD, Bailey LB, Shelnutt KP, Dunwoody KM, Maneval DR, Davis SR, et al. Methionine synthase reductase 66A → G polymorphism is associated with increased plasma homocysteine concentration when combined with the homozygous methylenetetrahydrofolate reductase 677C → T variant. J Nutr. 2004;134:2985–90.PubMedCrossRef Vaughn JD, Bailey LB, Shelnutt KP, Dunwoody KM, Maneval DR, Davis SR, et al. Methionine synthase reductase 66A → G polymorphism is associated with increased plasma homocysteine concentration when combined with the homozygous methylenetetrahydrofolate reductase 677C → T variant. J Nutr. 2004;134:2985–90.PubMedCrossRef
11.
go back to reference Jhee KH, Kruger WD. The role of cystathionine beta-synthase in homocysteine metabolism. Antioxid Redox Signal. 2005;7:813–22.PubMedCrossRef Jhee KH, Kruger WD. The role of cystathionine beta-synthase in homocysteine metabolism. Antioxid Redox Signal. 2005;7:813–22.PubMedCrossRef
12.
go back to reference Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993;57:47–53.PubMedCrossRef Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993;57:47–53.PubMedCrossRef
13.
go back to reference Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015–22.CrossRef Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015–22.CrossRef
14.
go back to reference Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherotrombotic disease. Lab Invest. 2001;81:645–72.PubMedCrossRef Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherotrombotic disease. Lab Invest. 2001;81:645–72.PubMedCrossRef
15.
go back to reference Katsiki N, Perez-Martinez P, Mikhailidis DM. Homocysteine and non-cardiac vascular disease. Curr Pharm Des. 2017;23:3224–32.PubMed Katsiki N, Perez-Martinez P, Mikhailidis DM. Homocysteine and non-cardiac vascular disease. Curr Pharm Des. 2017;23:3224–32.PubMed
16.
go back to reference Smith DA, Refsum H. Homocysteine, B vitamins and cognitive impairment. Annu Rev Nutr. 2016;36:211–39.PubMedCrossRef Smith DA, Refsum H. Homocysteine, B vitamins and cognitive impairment. Annu Rev Nutr. 2016;36:211–39.PubMedCrossRef
17.
go back to reference Moretti R, Caruso P, Dal Ben M, Conti C, Gazzin S, Tiribelli C. Vitamin D, homocysteine and folate in subcortical vascular dementia and Alzheimer dementia. Front Aging Neurosci. 2017;9:169.PubMedPubMedCentralCrossRef Moretti R, Caruso P, Dal Ben M, Conti C, Gazzin S, Tiribelli C. Vitamin D, homocysteine and folate in subcortical vascular dementia and Alzheimer dementia. Front Aging Neurosci. 2017;9:169.PubMedPubMedCentralCrossRef
18.
go back to reference Kundi H, Kiziltunc E, Ates I, Cetin M, Barca AN, Ozkayar N, et al. Association between plasma homocysteine levels and end-organ damage in newly diagnosed type 2 diabetes mellitus patients. Endocr Res. 2017;42:36–41.PubMedCrossRef Kundi H, Kiziltunc E, Ates I, Cetin M, Barca AN, Ozkayar N, et al. Association between plasma homocysteine levels and end-organ damage in newly diagnosed type 2 diabetes mellitus patients. Endocr Res. 2017;42:36–41.PubMedCrossRef
19.
go back to reference Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Int Med. 2004;140:94–100.PubMedCrossRef Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Int Med. 2004;140:94–100.PubMedCrossRef
20.
go back to reference Looker HC, Fagot-Campagna A, Gunter EW, Pfeiffer CM, Narayan KM, Knowler WC, et al. Homocysteine as a risk factor for nephropathy and retinopathy in type 2 diabetes. Diabetologia. 2003;46:766–72.PubMedCrossRef Looker HC, Fagot-Campagna A, Gunter EW, Pfeiffer CM, Narayan KM, Knowler WC, et al. Homocysteine as a risk factor for nephropathy and retinopathy in type 2 diabetes. Diabetologia. 2003;46:766–72.PubMedCrossRef
21.
go back to reference Sreckovic B, Sreckovic VD, Soldatovic I, Colak E, Sumarac-Dumanovic M, Janeski H, et al. Homocysteine is a marker for metabolic syndrome and atherosclerosis. Diabetes Metab Syndr. 2017;11:179–82.PubMedCrossRef Sreckovic B, Sreckovic VD, Soldatovic I, Colak E, Sumarac-Dumanovic M, Janeski H, et al. Homocysteine is a marker for metabolic syndrome and atherosclerosis. Diabetes Metab Syndr. 2017;11:179–82.PubMedCrossRef
22.
go back to reference Hajer GR, van der Graaf Y, Olijhoek JK, Verhaar MC, Visseren FL, SMART Study Group. Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome. Heart. 2007;93:216–20.PubMedCrossRef Hajer GR, van der Graaf Y, Olijhoek JK, Verhaar MC, Visseren FL, SMART Study Group. Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome. Heart. 2007;93:216–20.PubMedCrossRef
23.
go back to reference Yakub M, Schulze KJ, Khatry SK, Stewart CP, Christian P, West KP. High plasma homocysteine increases risk of metabolic syndrome in 6 to 8 year old children in rural Nepal. Nutrients. 2014;6:1649–61.PubMedPubMedCentralCrossRef Yakub M, Schulze KJ, Khatry SK, Stewart CP, Christian P, West KP. High plasma homocysteine increases risk of metabolic syndrome in 6 to 8 year old children in rural Nepal. Nutrients. 2014;6:1649–61.PubMedPubMedCentralCrossRef
24.
go back to reference Vayá A, Rivera L, Hernández-Mijares A, de la Fuente M, Solá E, Romagnoli M, et al. Homocysteine levels in morbidly obese patients: its association with waist circumference and insulin resistance. Clin Hemorheol Microcirc. 2012;52:49–56.PubMed Vayá A, Rivera L, Hernández-Mijares A, de la Fuente M, Solá E, Romagnoli M, et al. Homocysteine levels in morbidly obese patients: its association with waist circumference and insulin resistance. Clin Hemorheol Microcirc. 2012;52:49–56.PubMed
25.
go back to reference Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8:CD006612.PubMed Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8:CD006612.PubMed
26.
go back to reference Katsiki N, Mikhailidis DP. Emerging vascular risk factors in women: any differences from men? Curr Med Chem. 2015;22:3565–79.PubMedCrossRef Katsiki N, Mikhailidis DP. Emerging vascular risk factors in women: any differences from men? Curr Med Chem. 2015;22:3565–79.PubMedCrossRef
27.
go back to reference Piazzolla G, Castrovilli A, Liotino V, Vulpi MR, Fanelli M, Mazzocca A, et al. Metabolic syndrome and chronic obstructive pulmonary disease (COPD): the interplay among smoking, insulin resistance and vitamin D. PLoS ONE. 2017;12:e0186708.PubMedPubMedCentralCrossRef Piazzolla G, Castrovilli A, Liotino V, Vulpi MR, Fanelli M, Mazzocca A, et al. Metabolic syndrome and chronic obstructive pulmonary disease (COPD): the interplay among smoking, insulin resistance and vitamin D. PLoS ONE. 2017;12:e0186708.PubMedPubMedCentralCrossRef
28.
go back to reference Mursleen MT, Riaz S. Implication of homocysteine in diabetes and impact of folate and vitamine B12 in diabetic population. Diabetes Metab Syndr. 2017;11:S141–6.PubMedCrossRef Mursleen MT, Riaz S. Implication of homocysteine in diabetes and impact of folate and vitamine B12 in diabetic population. Diabetes Metab Syndr. 2017;11:S141–6.PubMedCrossRef
29.
go back to reference Hayden MR, Tyagi SC. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus and atheroscleropathy: the pleiotropic effects of folate supplementation. Nutr J. 2004;3:4.PubMedPubMedCentralCrossRef Hayden MR, Tyagi SC. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus and atheroscleropathy: the pleiotropic effects of folate supplementation. Nutr J. 2004;3:4.PubMedPubMedCentralCrossRef
30.
go back to reference American Diabetes Association. Standards of Medical Care in Diabetes-2018 Abridged for primary care providers. Clin Diabetes. 2018;36:14–37.PubMedCentralCrossRef American Diabetes Association. Standards of Medical Care in Diabetes-2018 Abridged for primary care providers. Clin Diabetes. 2018;36:14–37.PubMedCentralCrossRef
31.
go back to reference Xu C, Wu Y, Liu G, Liu X, Wang F, Yu J. Relationship between homocysteine level and diabetic retinopathy: a systematic review and meta-analysis. Diagn Pathol. 2014;9:167.PubMedPubMedCentralCrossRef Xu C, Wu Y, Liu G, Liu X, Wang F, Yu J. Relationship between homocysteine level and diabetic retinopathy: a systematic review and meta-analysis. Diagn Pathol. 2014;9:167.PubMedPubMedCentralCrossRef
32.
33.
go back to reference Mao S, Xiang W, Huang S, Zhang A. Association between homocysteine status and the risk of nephropathy in type 2 diabetes mellitus. Clin Chim Acta. 2014;431:206–10.PubMedCrossRef Mao S, Xiang W, Huang S, Zhang A. Association between homocysteine status and the risk of nephropathy in type 2 diabetes mellitus. Clin Chim Acta. 2014;431:206–10.PubMedCrossRef
34.
go back to reference Wang H, Cui K, Xu K, Xu S. Association between plasma homocysteine and progression of early nephropathy in type 2 diabetic patients. Int J Clin Exp Med. 2015;8:11174–80.PubMedPubMedCentral Wang H, Cui K, Xu K, Xu S. Association between plasma homocysteine and progression of early nephropathy in type 2 diabetic patients. Int J Clin Exp Med. 2015;8:11174–80.PubMedPubMedCentral
35.
go back to reference Tak YJ, Jeong DW, Kim YJ, Lee SY, Lee JG, Song SH, et al. Hyperhomocysteinaemia as a potential marker of early renal function decline in middle-aged Asian people without chronic kidney disease. Int Urol Nephrol. 2016;48:239–48.PubMedCrossRef Tak YJ, Jeong DW, Kim YJ, Lee SY, Lee JG, Song SH, et al. Hyperhomocysteinaemia as a potential marker of early renal function decline in middle-aged Asian people without chronic kidney disease. Int Urol Nephrol. 2016;48:239–48.PubMedCrossRef
36.
go back to reference Kernan WN, Obviagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Peripherl Vascular Disease, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemick attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–236.CrossRefPubMed Kernan WN, Obviagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Peripherl Vascular Disease, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemick attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–236.CrossRefPubMed
37.
go back to reference Towfighi A, Arshi B, Markovic D, Obviagele B. Homocysteine-lowering therapy and risk of recurrent stroke, myocardial infarction and death: the impact of age in the VISP trial. Cerebrovasc Dis. 2014;37:263–7.PubMedCrossRef Towfighi A, Arshi B, Markovic D, Obviagele B. Homocysteine-lowering therapy and risk of recurrent stroke, myocardial infarction and death: the impact of age in the VISP trial. Cerebrovasc Dis. 2014;37:263–7.PubMedCrossRef
38.
go back to reference Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E, Heart Outcomes Prevention Evaluation 2 Investigators. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke. 2009;40(1365):72. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E, Heart Outcomes Prevention Evaluation 2 Investigators. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke. 2009;40(1365):72.
39.
go back to reference Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, CSPPT Investigators, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015;313:1325–35.PubMedCrossRef Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, CSPPT Investigators, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015;313:1325–35.PubMedCrossRef
40.
go back to reference Qin X, Li J, Spence JD, Zhang Y, Li Y, Wang X, et al. Folic acid therapy reduces the first stroke risk associated with hypercholesterolemia among hypertensive patients. Stroke. 2016;47:2805–12.PubMedCrossRef Qin X, Li J, Spence JD, Zhang Y, Li Y, Wang X, et al. Folic acid therapy reduces the first stroke risk associated with hypercholesterolemia among hypertensive patients. Stroke. 2016;47:2805–12.PubMedCrossRef
41.
go back to reference Yang HT, Lee M, Hong KS, Ovbiagele B, Saver JL. Efficacy of folic acid supplementation in cardiovascular disease prevention: an updated meta-analysis of randomized controlled trials. Eur J Intern Med. 2012;23:745–54.PubMedCrossRef Yang HT, Lee M, Hong KS, Ovbiagele B, Saver JL. Efficacy of folic acid supplementation in cardiovascular disease prevention: an updated meta-analysis of randomized controlled trials. Eur J Intern Med. 2012;23:745–54.PubMedCrossRef
42.
go back to reference Zeng R, Xu CH, Xu YN, Wand YL, Wang M. The effect of folate fortification on folic acid-based homocysteine-lowering intervention and stroke risk: a meta-analysis. Public Health Nutr. 2015;18:1514–21.PubMedCrossRef Zeng R, Xu CH, Xu YN, Wand YL, Wang M. The effect of folate fortification on folic acid-based homocysteine-lowering intervention and stroke risk: a meta-analysis. Public Health Nutr. 2015;18:1514–21.PubMedCrossRef
43.
go back to reference Zhang Q, Li S, Li L, Li Q, Ren K, Sun X, et al. Metformin treatment and homocysteine: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2016;8:798.PubMedCentralCrossRef Zhang Q, Li S, Li L, Li Q, Ren K, Sun X, et al. Metformin treatment and homocysteine: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2016;8:798.PubMedCentralCrossRef
44.
go back to reference Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2019 executive summary. Endocr Pract. 2019;25:69–100.PubMedCrossRef Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2019 executive summary. Endocr Pract. 2019;25:69–100.PubMedCrossRef
Metadata
Title
Hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome
Authors
Giuseppina Piazzolla
Mafalda Candigliota
Margherita Fanelli
Anna Castrovilli
Elsa Berardi
Gianfranco Antonica
Stefano Battaglia
Vincenzo Solfrizzi
Carlo Sabbà
Cosimo Tortorella
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2019
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-019-0484-0

Other articles of this Issue 1/2019

Diabetology & Metabolic Syndrome 1/2019 Go to the issue